ASCO Brain Cancer

High-dose chemotherapy plus conventional radiotherapy resulted in a high 3-year overall survival in children and adolescents with newly diagnosed medulloblastoma and supratentorial primitive neuroectodermal tumor.

Addition of the drug armodafinil did not improve measures of fatigue in patients with gliomas undergoing treatment with radiotherapy, according to the results of a study presented at the 2014 ASCO Annual Meeting.

Researchers identified a six-gene signature that can help to predict the 3-year survival outcome for patients with grade II or grade III gliomas, independent of the patient’s histology, grade, and IDH1 mutations status.